NM_002878.4:c.1A>G
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 2P and 1B. PVS1_SupportingPP5BS2_Supporting
The NM_002878.4(RAD51D):c.1A>G(p.Met1?) variant causes a start lost change. The variant allele was found at a frequency of 0.00000435 in 1,611,004 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_002878.4 start_lost
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 1 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152188Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000406 AC: 1AN: 246458Hom.: 0 AF XY: 0.00000748 AC XY: 1AN XY: 133720
GnomAD4 exome AF: 0.00000343 AC: 5AN: 1458698Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 725818
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152306Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74482
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 4 Pathogenic:2Uncertain:1
In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 127884). Disruption of the initiator codon has been observed in individual(s) with ovarian cancer and colon polyps and colon or ovarian cancer and a personal or family history of breast and/or ovarian cancer (PMID: 24130102, 26681312, 27978560, 30322717). This variant is present in population databases (rs561425038, gnomAD 0.006%). This sequence change affects the initiator methionine of the RAD51D mRNA. The next in-frame methionine is located at codon 16. -
- -
- -
Hereditary cancer-predisposing syndrome Pathogenic:2
This variant results in the loss of translation initiator codon of the RAD51D gene. Although functional studies have not been reported, this variant is expected to result in an absent or non-functional protein product. It has been shown that the highly conserved RAD51D N-terminus (a.a. 1-83) encodes the single-stranded DNA binding domain and that the 13-residue N-terminal tail (a.a. 1-13) contributes to proper protein folding via hydrophobic interactions between side chains of the N-terminal tail and alpha helices of the single-stranded DNA binding domain (PMID: 21111057). These findings suggest that the production of a full-length protein from p.Met1 is important for RAD51 function. While an in-frame methionine occurs at codon 16, it is not known if it can serve as an alternative translation initiation site to produce a functional RAD51D protein. This variant has been reported in an individual affected with ovarian cancer (PMID: 26681312) and in an individual affected with colorectal cancer (PMID: 27978560). A different nucleotide substitution with the same protein effect (c.1A>T) has also been reported in an individual affected with breast and ovarian cancer (PMID: 24130102). This variant has been identified in 1/246458 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. -
The p.M1? pathogenic mutation (also known as c.1A>G) is located in coding exon 1 of the RAD51D gene and results from a A to G substitution at nucleotide position 1. This alters the methionine residue at the initiation codon (ATG). This alteration has been reported in unrelated women with ovarian cancer (Susswein LR et al. Genet. Med. 2016 Aug;18(8):823-32; Cardoso FC et al. Hum. Genomics, 2018 08;12:39; Carter NJ et al. Gynecol Oncol. 2018 12;151(3):481-488) as well as in a woman with early onset mismatch repair proficient colorectal cancer (Pearlman R et al. JAMA Oncol. 2017 Apr;3(4):464-471). In addition to the clinical data presented in the literature, sequence variations that modify the initiation codon are expected to result in either loss of translation initiation, N-terminal truncation, or cause a shift in the mRNA reading frame. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Hereditary breast ovarian cancer syndrome Pathogenic:1Uncertain:1
- -
Bewertung aller Varianten die das Startcodon betreffen im September!; According to the ACMG SVI adaptation criteria we chose these criteria: PVS1 (strong pathogenic): Frage zu PVS1-Bewertungsstärke: laut canvig RAD51C/D (=> Use ATM PVS1 Decision Tree): PVS1, (pathogene Variante upstream vom nächsten Startcodon) wie bewerten wir es? laut Toyun: PVS1-mod (pathogene Variante upstream vom nächsten Startcodon) Funktionelle Analyse: DNA BIndeDomäne , PM2 (supporting pathogenic): 1x in gnomAD V2 (non cancer oder all); 2x in gnomAD V3 (non cancer oder all) -
Gastric cancer Pathogenic:1
- -
not provided Pathogenic:1
Initiation codon variant in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 26681312, 24130102, 27978560, 30103829) -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at